Elfström Sigrid, Rosengren Anna, Andersson Rebecca, Engelbrektsson Johanna, Isaksson Albin, Meregalli Micaela, van Leuven Livia, Lalouni Maria, Öst Lars-Göran, Ghaderi Ata, Åhlén Johan
Department of Global Public health, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
J Child Psychol Psychiatry. 2025 Sep;66(9):1345-1356. doi: 10.1111/jcpp.14151. Epub 2025 Mar 12.
Pediatric anxiety disorders are prevalent, particularly among children with anxious parents. This trial evaluated a program for anxious parents aimed at preventing offspring anxiety disorders and symptoms over 12 months.
This parallel, randomized, controlled, open-label trial was conducted at Karolinska Institutet, Stockholm, Sweden. Inclusion criteria comprised heightened parental anxiety and the child (5-9 years old) not currently meeting criteria for an anxiety disorder. The program, Confident Parents-Brave Children (CPBC) involves six video conferencing group sessions. An external researcher randomly allocated (1:1) participants to CPBC or a self-help control. The primary outcome was change in clinical severity ratings (CSR) between pre- and 12-month assessments, assessed by the Anxiety Disorders Interview Schedule. Secondary outcomes included parent-rated child anxiety symptoms and parental self-efficacy. The study was preregistered at ClinicalTrials.gov (NCT04722731).
The trial included 215 parents (91% female) and 277 children (48% girls, mean age 7.0). At the 12-month assessment, no statistically significant difference was found between conditions on the primary outcome (change in CSR), OR = 0.67 (95% CI: 0.30, 1.48). No statistically significantly lower prevalence of anxiety disorder at the 12-month assessment was found in the CPBC group compared with the control group, OR = 0.57 (95% CI: 0.24, 1.31). When stratifying by age, children 5-6 years in CPBC showed lower risk of increased CSR, OR = 0.24 (95% CI: 0.08, 0.77), and anxiety diagnosis, OR = 0.23 (95% CI: 0.05, 0.84), compared to controls. Regarding secondary outcomes, CPBC children exhibited larger decreases in anxiety symptoms than control children from pre- to the 12-month assessment, Cohen's d = .35 (95% CI: 0.15, 0.55). Parents in both conditions showed increased parental self-efficacy over time, with no significant between-group effect. The 12-month assessment was completed by 204 parents (95%).
The CPBC may have potential for preventing anxiety in young children; however, further research is warranted.
儿童焦虑症很常见,尤其是在父母焦虑的儿童中。本试验评估了一项针对焦虑父母的项目,旨在预防其子女在12个月内出现焦虑症及症状。
这项平行、随机、对照、开放标签试验在瑞典斯德哥尔摩的卡罗林斯卡学院进行。纳入标准包括父母焦虑程度较高且孩子(5 - 9岁)目前未达到焦虑症标准。该项目“自信父母 - 勇敢孩子”(CPBC)包括六次视频会议小组课程。一名外部研究人员将参与者随机(1:1)分配到CPBC组或自助对照组。主要结局是通过焦虑症访谈量表评估的12个月评估前后临床严重程度评分(CSR)的变化。次要结局包括父母评定的孩子焦虑症状和父母自我效能感。该研究已在ClinicalTrials.gov(NCT04722731)上预先注册。
该试验纳入了215名父母(91%为女性)和277名儿童(48%为女孩,平均年龄7.0岁)。在12个月评估时,主要结局(CSR变化)在两组之间未发现统计学上的显著差异,OR = 0.67(95%CI:0.30,1.48)。与对照组相比,CPBC组在12个月评估时焦虑症患病率没有统计学上的显著降低,OR = 0.57(95%CI:0.24,1.31)。按年龄分层时相比对照组,CPBC组中5 - 6岁的儿童CSR增加风险较低,OR = 0.24(95%CI:0.08,0.77),焦虑症诊断风险较低,OR = 0.23(95%CI:0.05,0.84)。关于次要结局,从评估前到12个月,CPBC组儿童的焦虑症状下降幅度大于对照组儿童,Cohen's d = 0.